Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Doubles Q2 Revenues, Trims Loss

NEW YORK (GenomeWeb News) – Nanosphere reported after the close of the market Tuesday that its second-quarter revenues doubled and it trimmed its net loss on lower R&D spending.

The Northbrook, Ill.-based molecular diagnostics firm generated revenues of $402,237 for the three-month period ended June 30, compared to revenues of $194,715 for the second quarter of 2008. Its product sales increased to $242,740 from $194,715, while it also reported grant and contract revenue of $159,497, compared to no such revenues the year before.

"With the May 2009 FDA clearance of our influenza and respiratory syncytial virus (RSV) test along with the [cystic fibrosis] assay, we have expanded our test menu to four products with four more in the pipeline," Nanosphere President and CEO William Moffitt said in a statement. "These include the assay for hemochromatosis, the second generation version of the Verigene System that incorporates automated sample processing, a second generation flu and our troponin assays."

Nanosphere's net loss for the quarter was $8.4 million, or $.38 per share, down from $9.8 million, or $.44 per share, for the second quarter of 2008. Its EPS match analysts' consensus estimate for the quarter.

The company cut its R&D spending 27 percent to $4.4 million from $6 million and its SG&A spending 3 percent to 43.7 million from $3.8 million.

Nanosphere held cash and cash equivalents of $58.2 million as of the end of the quarter.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.